Evaluation of Neuroprotective Effect of Minocycline (minocyclin &RD)

S

Shahid Beheshti University of Medical Sciences

Status and phase

Unknown
Phase 2

Conditions

Retinal Detachment

Treatments

Drug: Minocycline
Drug: placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT01297816
89122

Details and patient eligibility

About

This process appears as a incredible and progressive event that will not stop till reattachment of RPE and neurosensory retina happened . Process of degeneration begins from first hours of RD (Retinal Detachment) establishment Neuroprotection of photoreceptor following RD is a novel and debatable discussion encountered in recent years . How to stop this phenomena and neuroprotective agent role in this issue are a new interest of researcher. In the study the investigators are planning to perform a clinical trial to demonstrate the minocycline neuroprotective effect in a double blind design as this impact has been implicated previously in a animal study

Sex

All

Ages

8+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • age over 8 years old
  • gender of both sex
  • normal liver and renal function
  • informed consent received from all patients
  • no pregnancy and no lactation
  • minimal sun exposure

Exclusion criteria

  • old RD
  • diabetic retina
  • previous retinal surgery CRF& liver disfunction RD + PVR > B Hyper sensitivity to tetracycline History previous MPC or PRP Patients unsuccessful SB (retina is off )

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Single Group Assignment

Masking

Double Blind

0 participants in 2 patient groups, including a placebo group

placebo
Placebo Comparator group
Description:
100mg-
Treatment:
Drug: placebo
minocyclin
Placebo Comparator group
Treatment:
Drug: Minocycline

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems